

AD _____
(Leave blank)

Award Number: W81XH-07-1-0403

TITLE: The Impact of a Common Mdm2 SNP on the Sensitivity of Breast Cancer To Treatment

PRINCIPAL INVESTIGATOR: Kim Marie Hirshfield, M.D., Ph.D.

CONTRACTING ORGANIZATION:
UMDNJ/Robert Wood Johnson Medical School,
Piscataway, New Jersey 08854

REPORT DATE: October 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

☒ Approved for public release; distribution unlimited

☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 06-06-2008		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 7 MAY 2007 - 6 MAY 2008	
4. TITLE AND SUBTITLE The Impact of a Common Mdm2 SNP on the Sensitivity of Breast Cancer To Treatment				5a. CONTRACT NUMBER W81XH-07-1-0403	
				5b. GRANT NUMBER W81XH-07-1-0403	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Kim Marie Hirshfield, M.D., Ph.D., Jin-Ming Yang, Ph.D., Bruce Haffty, M.D. Email:				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AND ADDRESS(ES) UMDNJ/Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, N.J 08854 The Cancer Institute of New Jersey, 195 Little Albany Street				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The discovery of a single nucleotide polymorphism (SNP) in the mdm2 promoter uncovered a previously unknown role of this SNP in predicting early onset of breast and the possibility that this germ line variation could decrease the effectiveness of treatment. These outcomes are likely due to the increased expression of mdm2 protein in SNP309 individuals, which blunts the p53-mediated apoptotic response to DNA damage. The objective of this proposal is to test the hypothesis that SNP309 decreases the effectiveness of radiation and chemotherapy in breast cancer and that this negative impact can be overcome by targeted down-regulation of mdm2. We observed that anti-estrogen agent, fulvestrant, causes a decrease in mdm2 protein half-life, leading to a reduction in mdm2 following treatment with this agent. We demonstrate that combined use of fulvestrant with chemotherapeutic drugs doxorubicin, etoposide and paclitaxel can enhance the sensitivity of breast cancer cells to these cytotoxic agents. We observed that mdm2 expression is differentially modulated by estrogen, the anti-estrogen tamoxifen, and genistein in a genotype-specific manner. The largest effects on reduction in mdm2 expression at the protein level occur in the mdm2 SNP309 cell line. We will continue to explore mechanistic studies in vitro while evaluating the clinical outcome associations of SNP309 to both chemotherapy and radiation therapy.					
15. SUBJECT TERMS mdm2, breast cancer, polymorphisms					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 13	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4-8
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	9
References.....	9
Appendices.....	9
Supplementary Data.....	9-13

INTRODUCTION

The recent discovery of a single nucleotide polymorphism (SNP) in the mdm2 promoter uncovered a previously unknown role of this SNP in predicting early onset of breast and the possibility that this germ line variation could decrease the effectiveness of treatment. These outcomes are likely due to the increased expression of mdm2 protein in SNP309 individuals, which blunts the p53-mediated apoptotic response to DNA damage. The objective of this proposal is to test the hypothesis that SNP309 decreases the effectiveness of radiation and chemotherapy in breast cancer patients and that this negative impact can be overcome by targeted down-regulation of mdm2. The rationale in support of these objectives are molecular epidemiological data showing that individuals harboring SNP309 are at increased risk for early onset breast cancer, and laboratory studies showing that SNP309 decreases the activity of DNA damaging agents. If we are to achieve better results of treatment for patients with breast cancer, the choice of treatment must eventually benefit from a more precise understanding of the genetic abnormalities that are present in each individual's tumor. Using the same dose of drug or amount of radiation for each breast cancer patient cannot possibly be consistent with our understanding of modern molecular medicine. For example, subtle variations in our genetic code (called single nucleotide polymorphisms, [SNPs "snips"]) exist in the human population and make us susceptible to certain diseases and resistant to others. Similarly, these polymorphisms can make us more or less sensitive to treatment. Since these polymorphisms exist both in breast cancer and in normal tissues, understanding their impact on both the patient and the tumor will eventually guide the choice and dose of drug and amount of irradiation. Therefore, our objective is to improve the ways in which patients with breast cancer are evaluated and treated through an understanding of subtle variations in the human genome. The proposal brings together a team of molecular biologists/epidemiologists, pharmacologists, radiation and medical oncologists, and statisticians to focus on this novel approach to breast cancer treatment. We anticipate that our results may be applicable to patients by the end of the three-year grant period.

BODY

Task 1. Determine the impact of mdm2 SNP309 on the results of breast irradiation

To date we have been primarily working on the database, updating and assuring complete clinical data, and processing the paperwork for IRB in accordance with recommendations from the IRB at CINJ and the human investigations committees of the DOD. Fortunately this has all now finally reached final approval by both bodies and we look forward to rapidly acquiring and processing the SNP309 data.

Task 2 Determine the impact of mdm2 SNP309 on the results of adjuvant chemotherapy

A total of 1329 women have been consented for participation in the study protocol as of August 15, 2008 (CINJ Protocol #040406, IRB# 0220044862). Of these, genomic DNA has been isolated from 980 patients. The information contained in this table reflects data

available from chart review for study participants (this chart review was completed as of May 5, 2008).

Table 1- Demographics of Study Cohort at The Cancer Institute of New Jersey.

Race	Number of Patients	% of Patients
African American	38	5.0
Asian	32	4.2
Caucasian	613	80.6
Hispanic	37	4.9
Indian	19	2.5
Other	22	2.9

Tumor Type	Number of Patients	% of Patients
Colloid/Mucinous	11	1.5
DCIS	63	8.4
Invasive Ductal	561	74.9
Invasive Lobular	82	11.0
LCIS/Atypical hyperplasia	5	0.7
Medullary	4	0.5
Metaplastic	4	0.5
Other	19	2.5

ER Status	Number of Patients	% of Patients
Positive	531	74.7
Negative	180	25.3

PR Status	Number of Patients	% of Patients
Positive	445	63.9
Negative	252	36.2

Her2/Neu Status	Number of Patients	% of Patients
Not amplified or 0-2+ IHC	420	80.8
Amplified or 3+ IHC	100	19.2
(all 2+ by IHC were reflexed for FISH)		

Stage	Number of Patients	% of patients
Control/LCIS/Atypical hyperplasia	5	0.7
0	62	8.9
1	260	37.1
IIA	161	23
IIB	105	15
IIIA	44	6.3
IIIB	25	3.6
IIIC	10	1.4
IV	28	4

Tumor	% of Patients
T0	5.2

T1	46.3
T2	24.7
T3	6.5
T4	4.6

Node status	
N0	47.6
N1	32.5
N2	3.7
N3	0.2

Metastatic Status	
M0	83.4
M1	3.5

Recurrence Status	% of patients
Yes	15.5
No	84.5

(excludes stage IV at diagnosis)

Distribution of times to recurrence for 91 patients (69% of recurrence occur by 5 years; most recurrences beyond this are ER+ tumors)		
Year(s) to recurrence	n	% of all recurrences
1	7	0.077
2	16	0.176
3	15	0.165
4	11	0.121
5	14	0.154
6	5	0.055
7	3	0.033
8-10	7	0.077
>10	13	0.143

Patients Receiving Each Treatment	No (%)	Yes (%)
Radiation	25	75
Chemotherapy	40	60
Hormonal therapy	25	75
Herceptin	90	10

We will be using this cohort to determine the genotype-specific recurrence free survival for the following: 1) hormone receptor positive and hormone receptor negative breast cancers; 2) hormone receptor positive breast cancer patients receiving hormonal therapy alone; 2) breast cancer patients receiving chemotherapy only (hormone receptor positive and negative disease); 3) breast cancer patients receiving chemotherapy followed by hormonal therapy (hormone receptor positive only).

Task 3 Determine the ability of anti-estrogens to restore drug and irradiation sensitivity by decreasing mdm2 expression

In this grant period, we have investigated the effects of anti-estrogen agent, fulvestrant, on mdm2 expression and sensitivity of human breast cancer cells to chemotherapeutic drugs. We found that in both MCF7 (T/G) and T47D (G/G) human breast cancer cell lines, fulvestrant decreases mdm2 expression to similar extents (Figure 1). Further, fulvestrant not only abolished the effect of estradiol (E₂), but also was able to suppress mdm2 protein levels below the control (no E₂) level (Figure 2). Mdm2 depletion by fulvestrant did not correlate with an increase in p53 activation (slight decrease) and no change in p21 levels was observed (Figure 3). Fulvestrant did not cause a reduction in mdm2 mRNA, but reduces mdm2 protein half-life (Figure 4). The combination of fulvestrant and chemotherapeutic drugs doxorubicin, etoposide or paclitaxel showed synergism in MCF7 and T47D cells (Figure 5).

Epidemiologic evidence suggests that genistein intake is inversely related to the risk of several tumors including breast cancer but its mechanism of action is not completely understood. However, conflicting data exists on the effect of genistein on the expression of the estrogen-dependent mdm2 gene. We hypothesized that if genistein acted like an anti-estrogen, it could bind estrogen receptor (ER), preventing binding to the ERE at the mdm2 promoter and lead to down-regulation of mdm2 expression. For those cells in which SNP309 is present, we anticipated even stronger effects. To explore this, we grew breast cancer cells under conditions of no estrogen (PF), normal media (N), with estradiol (E₂), with Tamoxifen (T), and with genistein (G). We selected three ER⁺ breast cancer cell lines representing the three mdm2 SNP309 genotypes: ZR75-1 (TT), MCF-7 (TG), and T47D (GG). Protein was isolated from the cells grown in the various conditions and Western blot analysis was performed (Figure 6).

In MCF-7 cells (TG), mdm2 protein is reduced when cells are grown in the absence of estrogen media as compared with normal media or with estradiol. With Tamoxifen or genistein, relative to estradiol, mdm2 was reduced, but remained at levels higher than that in the absence of estrogen. In T47D (GG genotype), the response in the absence of estrogen, normal media, and with estradiol treatment is similar to that of MCF-7 cells (TG genotype). However, by comparison, mdm2 levels are reduced to levels nearly equivalent to those in the absence of estrogen when treated with Tamoxifen and genistein. Of interest, the ~50kDa isoform of mdm2 is reduced further with genistein as compared with Tamoxifen, suggesting an effect on alternative splicing. In ZR75-1 cells (TT), no 50kDa isoform is expressed. In contrast to the MCF7 and T47D cells, genistein and Tamoxifen treatment resulted in **increased** mdm2. Increased expression may be the result of increased transcription or posttranslational changes leading to reduced degradation and longer half-life. These results suggest a genotype-specific effect of genistein and may explain contradictory effects observed in studies.

The P2 promoter of mdm2 has an ERE and we previously demonstrated that mdm2 levels are estradiol dose-dependent and genotype dependent (preliminary data for proposal). Therefore, we had hypothesized that Tamoxifen, an anti-estrogen that binds ER, would result in decreased mdm2 as well as decreased binding at the promoter as determined by chromatin immunoprecipitation (figure 7). While this was true in ZR75-1 cells and to a much lesser degree in MCF7 cells, binding occurred in the presence of Tamoxifen in

T47D. As genistein is thought of as an anti-estrogen, we hypothesized that genistein treatment would result in decreased binding to the ERE. With genistein treatment, ER still bound the P2 promoter region but transcription was reduced in MCF7 and T47D. Interestingly, binding appeared to be reduced in ZR75-1 for treatment with estradiol, Tamoxifen, and genistein. Since protein levels were increased in ZR75-1 with Tamoxifen and genistein, this suggests that post-translational modification leading to longer half-life may play a role in increased mdm2 levels with these treatments. It is not clear if this is truly a genotype-specific effect or if this is related to this particular cell line.

KEY RESEARCH ACCOMPLISHMENTS

- We observed that anti-estrogen agent, fulvestrant, causes a decrease in mdm2 protein half-life, leading to a reduction in mdm2 following treatment with this agent.
- We demonstrate that combined use of fulvestrant with chemotherapeutic drugs doxorubicin, etoposide and paclitaxel can enhance the sensitivity of breast cancer cells to these cytotoxic agents.
- We observed that mdm2 expression is differentially modulated by estrogen, the anti-estrogen tamoxifen, and genistein in a genotype-specific manner. The largest effects on reduction in mdm2 expression at the protein level occur in the mdm2 SNP309 cell line.
- We observed that binding of estrogen receptor alpha to the mdm2 promoter is less efficient in the wildtype mdm2 breast cell line in the presence of estrogen, tamoxifen, and genistein as compared with cell lines carrying at least one variant allele.
- We have accrued the patients needed to evaluate the role of SNP309 in mdm2 on outcomes associated with chemotherapy and hormonal therapy.

REPORTABLE OUTCOMES

Manuscript

None

Abstracts

Era of Hope poster

Degree obtained that are supported by this award

None

CONCLUSIONS

1. Selective estrogen receptor down-regulator, fulvestrant, decreases MDM2 expression and enhances sensitivity of human breast carcinoma cells to chemotherapeutic drugs (such as doxorubicin, etoposide and paclitaxel).
2. The anti-estrogen tamoxifen decreases MDM2 expression in a genotype-specific manner.

REFERENCES: none

APPENDICES: none

SUPPORTING DATA

Figure 1




Figure 1. Effect of the antiestrogen fulvestrant on expression of estrogen receptor and mdm2 proteins. Two breast cancer cell lines MCF7 and T47D were grown at various concentrations (0-10 micromolar) of fulvestrant for 66 hours. Protein was then harvested and levels of estrogen receptor and mdm2 were assayed by Western blot. The upper plots demonstrate the dose-dependent reduction of both proteins in each cell line.

Figure 2




Figure 2. Effect of the antiestrogen fulvestrant on mdm2 levels in breast cancer cells grown in the presence of estradiol. Two breast cancer cell lines MCF7 and T47D were grown in the presence of estradiol, and estradiol with one of two concentrations of fulvestrant. The lower plots represent the Western blot analysis corresponding to the quantification in the upper graphs.

Figure 3

MCF7: T/G; p53 wt




Figure 3. Effect of estradiol and the antiestrogen fulvestrant on p53 and p21 in breast cancer cell lines. The breast cancer cell lines MCF7 was grown in estradiol alone or with the presence of 10micromolar fulvestrant. Protein was harvested and Western blot analysis performed to detect p53 and p21. The lower plot depicts the Western blot for each protein using actin as a loading control. This plot was used to quantitate protein levels expressed in the upper curves.

Figure 4




Figure 4. Effect of fulvestrant on the half-life of mdm2 protein. Two breast cancer cell lines T47D and MCF7 were grown in the absence and the presence of the antiestrogen fulvestrant. Cells were treated with cycloheximide (CHX) and mdm2 protein expression was determined at various time points. The lower curves show Western Blot analyses from each cell type using actin as a loading control and were used to quantitate mdm2 levels given in the corresponding curves above.

Figure 5

CompuSyn Analysis:		
MCF7	Fulvestrant : Doxorubicin at constant ratio	1 : 0.5 Synergism
		1 : 0.015 Synergism
	Fulvestrant : Paclitaxel at constant ratio	1 : 0.025 Synergism / Additive
		1 : 0.0005 Synergism
	Fulvestrant : Etoposide at constant ratio	1 : 1 Synergism
T47D		1 : 5 Synergism
	Fulvestrant : Doxorubicin at constant ratio	1 : 0.25 Synergism / Additive
		1 : 0.0035 Synergism / Additive
	Fulvestrant : Paclitaxel at constant ratio	1 : 0.0125 Synergism / Antagonism
		1 : 0.0002 Synergism / Antagonism
	Fulvestrant : Etoposide at constant ratio	1 : 10 Synergism / Additive
		1 : 0.07 Synergism / Additive / Antagonism

Figure 5. Effect of combining the antiestrogen fulvestrant with doxorubicin, paclitaxel, or etoposide in two breast cancer cell lines. Analysis of cell response was determined using the CompuSyn program. Each combination was observed at two concentrations of chemotherapeutic agent while keeping the concentration of fulvestrant constant. The last column indicates the type observed effect of the combination for each drug and dose.




Figure 6. Western blot demonstrates mdm2 protein expression in three ER+ breast cancer cells lines representing the three SNP309 genotypes: ZR75-1 (TT), T47D (GG), MCF7 (TG). Cells were grown under different conditions: phenol-free, charcoal stripped media (PF), normal media (N), estradiol (E2), Tamoxifen (T), or genistein (G).




Figure 7. Chromatin immunoprecipitation using anti-ERα antibody with PCR of the mdm2 P2 promoter region was performed in the three ER+ breast cancer cell lines representing each of the three mdm2 genotypes.